A number of N-(indol-3-ylglyoxylyl)benzylamine derivatives were synthesized and tested for [H-3]flunitrazepam displacing activity in bovine brain membranes. Some of these derivatives (9, 12, 14, 15, 17, 27, 34, 35, 38, 41, and 45) exhibited high affinity for the benzodiazepine receptor (BzR) with K-i values ranging from 67 to 11 nM. The GABA ratio and [S-35]-tert-butylbicyclophosphorothionate binding data, determined for the most active compounds, showed that they elicit an efficacy profile at the BzR which depends on the kind of substituent present on the phenyl ring of the benzylamine moiety. Moreover, lengthening (propylamine derivatives 1-3) and shortening (aniline derivatives 46-54) of the distance between the phenyl ring and the amide group of the side chain gave compounds with a drastically lower binding potency. The biological results are discussed in the light of a recently proposed pharmacophore model and compared, by molecular modeling studies, with those obtained from effective BzR ligands.
Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies of N-(Indol-3-ylglyoxylyl)benzylamine Derivatives at the Benzodiazepine Receptor
DA SETTIMO PASSETTI, FEDERICO;MARINI, ANNA MARIA;MARTINI, CLAUDIA;GIANNACCINI, GINO;LUCACCHINI, ANTONIO
1996-01-01
Abstract
A number of N-(indol-3-ylglyoxylyl)benzylamine derivatives were synthesized and tested for [H-3]flunitrazepam displacing activity in bovine brain membranes. Some of these derivatives (9, 12, 14, 15, 17, 27, 34, 35, 38, 41, and 45) exhibited high affinity for the benzodiazepine receptor (BzR) with K-i values ranging from 67 to 11 nM. The GABA ratio and [S-35]-tert-butylbicyclophosphorothionate binding data, determined for the most active compounds, showed that they elicit an efficacy profile at the BzR which depends on the kind of substituent present on the phenyl ring of the benzylamine moiety. Moreover, lengthening (propylamine derivatives 1-3) and shortening (aniline derivatives 46-54) of the distance between the phenyl ring and the amide group of the side chain gave compounds with a drastically lower binding potency. The biological results are discussed in the light of a recently proposed pharmacophore model and compared, by molecular modeling studies, with those obtained from effective BzR ligands.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
